On May 06, 2014, Avanir Pharmaceuticals Inc (NASDAQ:AVNR), reported financial results for the three and six months ended March 31, 2014. Avanir Pharmaceuticals Inc (NASDAQ:AVNR), shares after opening at $4.52 moved to $4.66 on last trade day and at the end of the day closed at $4.44. Company price to sales ratio in past twelve months was calculated as 7.90 and price to cash ratio as 15.40. Avanir Pharmaceuticals Inc (NASDAQ:AVNR), showed a negative weekly performance of 10.84%.
Cytokinetics, Inc. (NASDAQ:CYTK), reported total revenues of $8.0 million for the first quarter of 2014, compared to $0.8 million during the same period in 2013. Net loss for the first quarter of 2014 was $8.7 million or $0.27 per basic share and diluted share. This is compared to a net loss for the same period in 2013, of $12.6 million, or $0.53 per basic and diluted share. As of March 31, 2014, cash, cash equivalents and investments totaled $101.9 million. Cytokinetics, Inc. (NASDAQ:CYTK), shares fell 6.32% in last trading session and ended the day on $4.15. Cytokinetics, Inc. (NASDAQ:CYTK), return on equity ratio is recorded as -65.90% and its return on assets is -40.80%. Cytokinetics, Inc. (NASDAQ:CYTK), yearly performance is -35.36%.
Sangamo Biosciences, Inc. (NASDAQ:SGMO), announced its earnings results on Tuesday. The company reported ($0.12) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.13) by $0.01,Analyst Ratings News reports. The company had revenue of $8.10 million for the quarter, compared to the consensus estimate of $6.59 million. Sangamo Biosciences, Inc. (NASDAQ:SGMO), shares moved down 8.98% in last trading session and was closed at $11.76, while trading in range of $ 11.56 – 13.18. Sangamo Biosciences, Inc. (NASDAQ:SGMO), year to date (YTD) performance is -15.33%.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), reported financial results for the first quarter ended March 31, 2014. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), weekly performance is -14.06%. On last trading day company shares ended up $2.75. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), distance from 50-day simple moving average (SMA50) is -25.08%. Analysts mean target Price for the company is $6.00.